Cargando…

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer

Despite recent improvements in treatment modalities, pancreatic cancer remains a highly lethal tumor with mortality rate increasing every year. Poly (ADP-ribose) polymerase (PARP) inhibitors are now used in pancreatic cancer as a breakthrough in targeted therapy. This study focused on whether PARP i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yali, Zheng, Kun, Xiong, Hua, Huang, Yongbiao, Chen, Xiuqiong, Zhou, Yilu, Qin, Wan, Su, Jinfang, Chen, Rui, Qiu, Hong, Yuan, Xianglin, Wang, Yihua, Zou, Yanmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718453/ https://www.ncbi.nlm.nih.gov/pubmed/34975854 http://dx.doi.org/10.3389/fimmu.2021.762989

Ejemplares similares

PARP inhibitors in gastric cancer: beacon of hope
por: Wang, Yali, et al.
Publicado: (2021)

A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration
por: Zheng, Kun, et al.
Publicado: (2022)

Association Between RSK2 and Clinical Indexes of Primary Breast Cancer: A Meta-Analysis Based on mRNA Microarray Data
por: Zheng, Kun, et al.
Publicado: (2021)

Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer
por: Wang, Yali, et al.
Publicado: (2021)

Multi-omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique sensitivity to first-line therapies
por: Zou, Yanmei, et al.
Publicado: (2022)

KRAS (G12C) mutation‐induced TOPK overexpression contributes to tumour progression in non‐small cell lung cancer
por: Cai, Chang, et al.
Publicado: (2023)

ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer
por: Liu, Dian, et al.
Publicado: (2020)

A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
por: Qin, Wan, et al.
Publicado: (2022)

Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma
por: Huang, Yongbiao, et al.
Publicado: (2020)

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
por: Tu, Jingyao, et al.
Publicado: (2022)

A Novel Prognostic Signature for Survival Prediction and Immune Implication Based on SARS-CoV-2–Related Genes in Kidney Renal Clear Cell Carcinoma
por: Huang, Yongbiao, et al.
Publicado: (2022)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma
por: Su, Jinfang, et al.
Publicado: (2022)

Frequently rearranged in advanced T-cell lymphomas-1 demonstrates oncogenic properties in prostate cancer
por: Zhang, Wei, et al.
Publicado: (2016)

PARP1 Upregulation in Recurrent Oral Cancer and Treatment Resistance
por: Wang, Feifei, et al.
Publicado: (2022)

Exploring the Prognostic Value, Immune Implication and Biological Function of H2AFY Gene in Hepatocellular Carcinoma
por: Huang, Yongbiao, et al.
Publicado: (2021)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
por: Quan, Chuntao, et al.
Publicado: (2023)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Quantitative Analysis of the Protein Methylome Reveals PARP1 Methylation is involved in DNA Damage Response
por: Wang, Xinzhu, et al.
Publicado: (2022)

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020)

SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity
por: Liu, Huiquan, et al.
Publicado: (2019)

Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy
por: Huang, Yongbiao, et al.
Publicado: (2022)

mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance
por: BU, CHIWEN, et al.
Publicado: (2023)

PRIMA-1(Met) suppresses colorectal cancer independent of p53 by targeting MEK
por: Lu, Tao, et al.
Publicado: (2016)

Integrated analysis reveals the protective mechanism and therapeutic potential of hyperbaric oxygen against pulmonary fibrosis
por: Yuan, Yuan, et al.
Publicado: (2022)

Hyperbaric Oxygen Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Yuan, Yuan, et al.
Publicado: (2021)

Uncoupling of PARP1 Trapping and Inhibition Using Selective PARP1 Degradation
por: Wang, Shuai, et al.
Publicado: (2019)

FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1
por: Huang, Tingting, et al.
Publicado: (2017)

Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells
por: Wang, Yihua, et al.
Publicado: (2019)

Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis
por: Deng, Ling, et al.
Publicado: (2017)

The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
por: Tu, Jingyao, et al.
Publicado: (2023)

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2
por: Zuo, Hao, et al.
Publicado: (2020)

Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
por: Wang, Lu, et al.
Publicado: (2020)

DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition
por: Viera, Talysa, et al.
Publicado: (2020)

The Different Effects of Atorvastatin and Pravastatin on Cell Death and PARP Activity in Pancreatic NIT-1 Cells
por: Chen, Ya-Hui, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qv8cjhtgn19e36npkd0lmmt198